Youngblood Brass Band

Unlearn Appoints Arman Sabbaghi, Ph.D. as Head of Biostatistics Research

Retrieved on: 
Thursday, January 12, 2023

Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Arman Sabbaghi, Ph.D. has been appointed Head of Biostatistics Research.

Key Points: 
  • Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Arman Sabbaghi, Ph.D. has been appointed Head of Biostatistics Research.
  • In this role, he will lead the company’s research and development activities to develop novel clinical trial applications that capitalize on the unique value of prognostic digital twins to reimagine the clinical trial for the 21st century.
  • “We are pleased to welcome Arman to the Unlearn team.
  • Arman earned a Masters and Ph.D. in Statistics from Harvard University and BS in Mathematics (with Honors) and Mathematical Statistics from Purdue University.

Unlearn Appoints Alex Lang, Ph.D. as Vice President, Technology

Retrieved on: 
Wednesday, November 16, 2022

Unlearn, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Alex Lang, Ph.D .

Key Points: 
  • Unlearn, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Alex Lang, Ph.D .
  • We are excited to welcome Alex to the Unlearn team.
  • Alex joins Unlearn from Cruise, a prominent driverless car company, where he was Senior Manager, Perception.
  • In this role, Alex directed multiple teams of engineers to successfully solve perception problems for autonomous vehicles.

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Retrieved on: 
Tuesday, April 19, 2022

Unlearn, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that it has closed a $50 million Series B funding round.

Key Points: 
  • Unlearn, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that it has closed a $50 million Series B funding round.
  • Unlearn works with pharma sponsors, biotech companies, and academic institutions to optimize human clinical trials with TwinRCTs.
  • We are excited to support the Unlearn team as they scale their TwinRCT solution to make clinical trials better for patients and for sponsors.
  • Unlearn.AI is the only company creating TwinRCTs, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials.